TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-reported height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total plasma homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with CAD or CAS complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Lactate dehydrogenase (LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Smoking cessation (quit) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of fatigue at week 6
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in level of fatigue up to week 24
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Serum atherogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Direct Current cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic value of clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of punch biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of surgical excision/Mohs micrographic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in hepatic steatosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Total Inflammation Burden Scoring (TIBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Annual mean percent change in hip bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of all-cause deaths
Endpoint domain: Mortality/survival
Primary endpoint: Change of intragastral pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in AUA symptom score index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with established etiological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Tirzepatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with definite or probable drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of HIV-positive members of a discordant partnership who initiate ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV viral load suppression of HIV-positive members of a discordant partnership
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV-negative members of a discordant partnership who initiate PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥2 point change in Clinical Activity Score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of distant best-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4 Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease activity measured by AS-DAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CD4+ T Cell-associated HIV RNA Transcription Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Alternative Beliefs Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stable or Improved Polyneuropathy Disability (PND) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of bronchoscopy to predict post-extubation stridor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Iris Pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of menstrual blood loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective feeling of energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUC of study medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlations between capsule and fecal markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Amount of 24 Hour Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Rolimeter Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PRO Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Intestinal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of (S)-ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of (S)-ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Symptom Scale-Self-Report (PSS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin independence with adequate control of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen uptake during cardiopulmonary exercise testing (% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial pO2 in mmHg at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial pCO2 at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Validity of cardiac index measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fugl-Meyer Assessment of Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Pulmonary embolism within 72 hrs after ED visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emotional Eating Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Response (FSH Level + Vaginal Bleeding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Optimum tube size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients free from progression and alive
Endpoint domain: Mortality/survival
Primary endpoint: development of significant CAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of adrenal crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence rate of conserving woman's uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety as assessed by Vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overview of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting a Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Vertical, apical and coronal horizontal deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in CVD-related emergency department visits and hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment related toxicity-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in corporal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants recruited/number of patients approached (consent rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of adverse event reports, severe adverse event alerts and patient deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Use of hospital services (triage calls, acute admissions, ward stays)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diabetes self-care activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stone free rate after SWL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change acylated ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Exclusive breastfeeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Dietary intake improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of abnormal ECG (QTc > 450)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Weight Change From Baseline at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inter-observer reliability of stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attitudes towards CPR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experience in performing CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant elevation of ALT or AST
Endpoint domain: Adverse events/effects
Primary endpoint: maximal tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: dose limiting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of neurotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood outgrowth endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acetylcarnitine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of inadequate gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access and adherence to prenatal iron and folic acid supplements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cell treatment-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in subject's leg swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subject's leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum sL1CAM level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular velocity of the non-affected arm raising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overdose mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reported cases of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of conditioning regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Person-Centered Care Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Repigmentation of the affected area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: prevalence rate of valvular ATTR amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Patients with a Secondary Diagnoses of Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: iron overload on T2* MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: %O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased willingness for pre-exposure prophylaxis (PrEP) uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Echocardiographic ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Demonstration of Ischemia (≤0.80)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Port site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean and maximum standardised uptake values (SUV) of fluciclatide for the myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation with the severity of aortic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation with the volume of myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of recatheterization due to urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers to HPV Type 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers to HPV Type 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers to HPV Type 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers to HPV Type 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers to HPV Type 31
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heart failure stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Discontinued Study Due to Side-effects of the Medication
Endpoint domain: Adverse events/effects
Primary endpoint: % Change in Hamilton Depression Rating Scale From Baseline to week8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mesolimbic Reward System Activity From Pre to Post Treatment (8 Weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Periodic Limb Movements per hour of Sleep (PLMS index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Blood Oxygen Level Dependent - Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the result of Box and blocks test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactation Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Depressive disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal findings in electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the Curve (AUC) of dexamphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of dexamphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (T 1/2) of dexamphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Corneal Fluorescein Staining (tCFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Dryness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Quality of Life at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Symptomatic Brain Metastases
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Brain Metastases
Endpoint domain: Adverse events/effects
Primary endpoint: Cross sectional muscle area of the 1st vertebrae level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: initial wound hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percent graft take at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: outcome and cosmetic appearance at routine intervals up to 24 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Protein expression difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diurnal IOP at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of APSNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytogenetic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of serious adverse events (SAEs) and/or TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of the saphenous nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants where the procedure was technically performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants where the etiology of LUTO was correctly diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants where the posterior urethral valve were successfully released
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants whose fetal cystoscopy resulted in the prevention of post-natal severe pulmonary hypoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants whose fetal cystoscopy resulted in the prevention of post-natal severe renal impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: readiness to disclose
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Amount of Intravenous Morphine Self-administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain management outcomes
Primary endpoint: Bath ankylosing spondylitis disease index (BASDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bath ankylosing spondylitis functional index (BASFI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete or Partial Renal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Invasive Fungal Infection
Endpoint domain: Adverse events/effects
Primary endpoint: microvascular leak formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emergence Agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Health related quality of life in patients with CKD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mass of Peanuts Under Dentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in overall Quality of Life in Epilepsy-89 (QOLIE-89) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Profile of Mood States (POMS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of catheter thrombosis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Autoimmune bullous disease quality of life (ABQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life